Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.cytogfr.2020.07.010

http://scihub22266oqcxt.onion/10.1016/j.cytogfr.2020.07.010
suck pdf from google scholar
32665127!7334951!32665127
unlimited free pdf from europmc32665127    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32665127      Cytokine+Growth+Factor+Rev 2020 ; 54 (ä): 43-50
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Are we fully exploiting type I Interferons in today s fight against COVID-19 pandemic? #MMPMID32665127
  • Arico E; Bracci L; Castiello L; Gessani S; Belardelli F
  • Cytokine Growth Factor Rev 2020[Aug]; 54 (ä): 43-50 PMID32665127show ga
  • Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I) - mainly IFN-alpha and beta -represent ideal candidates given their direct and immune-mediated antiviral effects and the long record of clinical use. However, the best modalities of using these cytokines in SARS-CoV-2 infected patients is a matter of debate. Here, we discuss how we can exploit the current knowledge on IFN-I system to tailor the most promising dosing, timing and route of administration of IFN-I to the disease stage, with the final aim of making these cytokines a valuable therapeutic strategy in today's fight against COVID-19 pandemic.
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Betacoronavirus/*drug effects[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*prevention & control[MESH]
  • |Humans[MESH]
  • |Immunotherapy/methods[MESH]
  • |Interferon-alpha/*therapeutic use[MESH]
  • |Interferon-beta/*therapeutic use[MESH]
  • |Pandemics/*prevention & control[MESH]
  • |Pneumonia, Viral/*prevention & control[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box